Added to YB: 2026-10-08
Pitch date: 2026-10-04
RNAC [bullish]
Cartesian Therapeutics, Inc.
-10.6%
current return
Author Info
No bio for this author
Company Info
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
Market Cap
$211.5M
Pitch Price
$7.36
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.39
P/E
-1.25
EV/Sales
86.48
Sector
Biotechnology
Category
growth
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Cartesian Therapeutics, Inc.
RNAC (quick overview): Cartesian Therapeutics’ Descartes-08 is an mRNA CAR-T program with a credible registrational path in myasthenia gravis and potential to deliver an immune reset without conventional preconditioning lymphodepletion, potentially making the therapy easier to administer and less burdensome than traditional CAR-T. Broader autoimmune expansion offers upside, but the thesis depends on durable, meaningful efficacy and sufficient practicality to compete with chronic therapies.
Read full article (1 min)